Search
Nkarta Inc
NKTXAdd to Watchlist
2.090USD
-0.060-2.79%
Close 07-31 16:00（ET）Quotes delayed by 15 min
149.53MMarket Cap
LossP/E TTM
More Details of Nkarta Inc Company
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Nkarta Inc Info
Ticker SymbolNKTX
Company nameNkarta Inc
IPO dateJul 10, 2020
CEOHastings (Paul J)
Number of employees157
Security typeOrdinary Share
Fiscal year-endJul 10
Address1150 Veterans Boulevard
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone19254071049
Websitehttps://www.nkartatx.com/
Ticker SymbolNKTX
IPO dateJul 10, 2020
CEOHastings (Paul J)
Company Executives of Nkarta Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
159.87K
-1.11%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Angela Thedinga
Ms. Angela Thedinga
Independent Director
Independent Director
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
159.87K
-1.11%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Nkarta Inc?
The top five shareholders of Nkarta Inc are: Mr. Paul J. Hastings
How many institutions hold shares of Nkarta Inc (NKTX)?
As of 2026Q1, 280 institutions hold shares of Nkarta Inc, with a combined market value of approximately 58.52M, accounting for 82.11% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -25744153.00.